150 N. RADNOR CHESTER ROAD, RADNOR, PA
Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
Other Events
Financial Results, Press Release
Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
News
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence